Bredicon Tablet 0.075 mg
Bredicon Tablet 0.075 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
Bredicon Tablet 0.075 mg is a progestogen structurally related to levonorgestrel that has been shown to reliably inhibit ovulation.
The effects of desogestrel are divided on reproductive including modification of luteinizing hormone and follicle stimulating hormone, declines on the onset of menstruation, and increases the viscosity of the vaginal fluid; and on metabolic that includes increase insulin secretion and resistance, increased lipase activity, and increased fat deposition. The effect of desogestrel on the lipids has been studied extensively and the results are contradictory.
Bredicon Tablet 0.075 mg main therapeutic effect due to its mechanism of action is known to be related to the inhibition of the ovulation in 97% of the cycles. This effect was proven in clinical trials in non-breastfeeding women from which the Pearl failure rate was reported to be of 0.17 per 100 women-years. This result indicated that desogestrel is more efficient when compared to other progestogen-only pills. All the therapeutic effect is produced by a transformation of the endometrium followed by an inhibition of the ovulation due to the suppression of other hormones.
Bredicon Tablet 0.075 mg has been widely confirmed to be related to an increase in the risk of venous thromboembolism due to the driven increased in blood coagulation factors, leading to a pronounced prothrombotic state. However, the effects of desogestrel are known to not impact significantly the level of total cholesterol remaining in the range of change of 10% which allows it to be a molecule that presents a favorable lipid profile.
| Trade Name | Bredicon Tablet 0.075 mg |
| Generic | Desogestrel |
| Desogestrel Other Names | Desogestrel, Désogestrel, Desogestrelum |
| Weight | 0.075 mg |
| Type | Tablet |
| Formula | C22H30O |
| Weight | Average: 310.473 Monoisotopic: 310.229665582 |
| Protein binding | The main metabolite of desogestrel is mainly found bound to albumin and sex-hormone binding globulin. Around 96-98% of the administered dose of desogestrel is found bound to plasma proteins from which 40-70% is found bound to sex-hormone binding globulin. |
| Groups | Approved |
| Therapeutic Class | Oral Contraceptive preparations |
| Manufacturer | Renata Limited |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Bredicon Tablet 0.075 mg used for prevention of pregnancy or oral contraception.
Bredicon Tablet 0.075 mg is also used to associated treatment for these conditions: Contraception
How Bredicon Tablet 0.075 mg works
Bredicon Tablet 0.075 mg enters the cell passively and acts by binding selectively to the progesterone receptor and generating low androgenic activity. Its binding produces an effect like a transcription factor and thus, it produces modifications in the mRNA synthesis.
The active metabolite of desogestrel, etonogestrel, presents a combination of high progestational activity with minimal intrinsic androgenicity.
Dosage
Bredicon Tablet 0.075 mg dosage
When used alone: 75 mcg daily when used alone.
For monophasic combined oral contraceptives: Typically, 150 mcg daily;
For triphasic combined oral contraceptives: 50-150 mcg daily.
Side Effects
Common- Irregular bleeding, amenorrhoea, headache, weight gain, breast pain, nausea, acne, mood changes, decreased libido. Less common- Vaginitis, dysmenorrhea, vomiting, alopecia, fatigue, difficulty wearing contact lenses. Rare- Rash, urticaria, erythema nodosum.
Toxicity
Administration of large quantities of desogestrel has been shown to produce strong hormonal effects but to lack chronic toxicity. The reported LD50 in rats after oral administration of desogestrel is higher than 2000 mg/kg. Overdose hasn't reported serious effects but only symptoms of nausea and withdrawal of bleeding.
Most reports haven't linked the administration of desogestrel with the increased risk of breast cancer. The increased risk has been reported to be related to the duration of use. However, several reports indicate a desogestrel-driven increased risk in cervical intra-epithelial neoplasia but the results are still not conclusive.
Precaution
Heart disease, sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, history of CV or renal impairment, DM, asthma, epilepsy, migraine, depression and thromboembolism; lactation.
Interaction
Reduced efficacy with enzyme-inducing drugs; aminoglutethimide. May inhibit ciclosporin metabolism.
Food Interaction
No interactions found.Volume of Distribution
The apparent volume of distribution of desogestrel is of 1.5 L/kg.
Elimination Route
After oral administration, desogestrel is rapidly absorbed and it reaches a peak concentration of 2 ng/ml after 1.5 hours. The bioavailability of desogestrel is reported to be in the range of 60-80% and the reported AUC is of 3000 ng.h/ml. Almost all the administered dose is modified to the active metabolite, etonogestrel.
Half Life
The terminal half-life of desogestrel is determined to be of 30 hours.
Clearance
The metabolic clearance rate of desogestrel is reported to be of about 2 ml/min/kg.
Elimination Route
The elimination of desogestrel is found to be mainly renal corresponding to about 6 times the dose eliminated in the bile. The elimination of desogestrel is only done as the metabolites and not as the unchanged drug and about 85% of the administered dose can be excreted as metabolites after 6-8 days.
Pregnancy & Breastfeeding use
Incase of known or suspected Bredicon Tablet 0.075 mg is contraindicated. Bredicon Tablet 0.075 mg does not influence the production or the quality (protein, lactose, or fat concentrations) of breast milk. From clinical trial it has been seen that it has no effect on the development and growth of a nursing infant.
Contraindication
Bredicon Tablet 0.075 mg is contraindicated in the following conditions: Known or suspected pregnancy; Active venous thromboembolic disorder; Presence or history of severe hepatic disease as long as liver function values have not returned to normal; Known or suspected sex-steroid sensitive malignancies; Undiagnosed vaginal bleeding; Hypersensitivity to the active substance or to any of the excipients.
Acute Overdose
There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in this case are nausea, vomiting and, in young girls, slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic.
Storage Condition
Store below 25° C in a cool, dry place. Keep away from light & out of reach of children.
Innovators Monograph
You find simplified version here Bredicon Tablet 0.075 mg
Bredicon Tablet 0.075 mg contains Desogestrel see full prescribing information from innovator Bredicon Tablet 0.075 mg Monograph, Bredicon Tablet 0.075 mg MSDS, Bredicon Tablet 0.075 mg FDA label
FAQ
What are the side effects of Bredicon Tablet 0.075 mg?
Nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change may occur. Vaginal bleeding between periods (spotting) or missed/irregular periods may occur, especially during the first few months of use.
Does Bredicon Tablet 0.075 mg cause weight gain?
With regards to changing your Pill to one less likely to affect weight, the Pills containing Bredicon Tablet 0.075 mg and gestodene types of progesterone hormone are suggested as less likely to cause weight gain.
What does Bredicon Tablet 0.075 mg do to my body?
The traditional progestogen-only pill (POP) prevents pregnancy by thickening the mucus in the cervix to stop sperm reaching an egg. The Bredicon Tablet 0.075 mg progestogen-only pill can also stop ovulation. The progestogen-only pill needs to be taken every day to work.
Does Bredicon Tablet 0.075 mg stop periods?
The Bredicon Tablet 0.075 mg pill (12-hour pill, Desogestrel) stops ovulation in 97% of menstrual cycles.
Does Bredicon Tablet 0.075 mg affect my mood?
Bredicon Tablet 0.075 mg is known to be commonly associated with mood changes, depressed mood and decreased libido Anxiety and panic attacks have however not yet been described with Bredicon Tablet 0.075 mg use.
Does Bredicon Tablet 0.075 mg make my breasts bigger?
Birth control pills Bredicon Tablet 0.075 mg can affect your breast size, they don't change breast size permanently.
At what age should I stop taking Bredicon Tablet 0.075 mg?
If you're healthy and you don't smoke, you can continue taking birth control pills after age 35. However, birth control pills aren't recommended if you're 35 or older and you smoke because of the risk of cardiovascular disease.
Is it normal to bleed on the Bredicon Tablet 0.075 mg pill?
Irregular bleeding or spotting is common in the first three to four months after you start taking the Bredicon Tablet 0.075 mg. This should subside once your body adjusts to the medication. You may experience spotting later on if you've missed or skipped a dose.
Can Bredicon Tablet 0.075 mg cause hair growth?
Bredicon Tablet 0.075 mg is low on the androgen index, and they can actually stimulate hair growth by keeping your hair in the anagen phase longer. Low-androgen birth control pills include: desogestrel-ethinyl estradiol (Desogen, Reclipsen)
Can Bredicon Tablet 0.075 mg cause night sweats?
Bredicon Tablet 0.075 mg appears to be associated with dry eyes, vulvovaginal dryness (atrophic vaginitis) and night sweats (nocturnal hyperhidrosis), according to a signal reported in the WHO Pharmaceutical Newsletter.
How long does Bredicon Tablet 0.075 mg take to work?
Bredicon Tablet 0.075 mg takes two days for the pill's contraceptive effect on cervical mucus to be re-established after missing a pill. If you are taking a 12-hour pill that stops ovulation (a desogestrel pill, such as Bredicon Tablet 0.075 mg), you will need additional contraception for two days.
Does Bredicon Tablet 0.075 mg cause water retention?
Bredicon Tablet 0.075 mg have previously been shown to increase sodium excretion3, demonstrating that sodium and associated fluid retention does not occur in the body during use of oral contraceptives containing 'traditional' progestogens.
Can Bredicon Tablet 0.075 mg make me crazy?
For some women, being on the Bredicon Tablet 0.075 mg can magnify these feelings, leading to anxiety disorders and depression. But if these things happen to you, it doesn't mean you're crazy; it just means you're on the wrong pill. Mood-related issues like anxiety and depression are super-common among women on the Bredicon Tablet 0.075 mg.
Can Bredicon Tablet 0.075 mg help with anxiety?
Hormonal contraception can cause feelings of anxiety in some people. But other users may find their birth control relieves anxiety symptoms.
Does Bredicon Tablet 0.075 mg make my boobs grow?
Starting to take Bredicon Tablet 0.075 mg can stimulate the breasts to grow. However, any increase in size is typically slight. Within a few months of taking the pill, the breasts generally return to their regular size. This usually also happens if a person stops taking Bredicon Tablet 0.075 mg.
Does Bredicon Tablet 0.075 mg cause blood clots?
Among those ages 25 to 49 taking Bredicon Tablet 0.075 mg, drospirenone or cyproterone, an additional 17 women per 10,000 will develop a blood clot.
Why is Bredicon Tablet 0.075 mg prescribed for?
Bredicon Tablet 0.075 mg is used to prevent pregnancy. It is a birth control pill when taken properly, prevents pregnancy. It works by stopping a woman's egg from fully developing each month.
Can I push my period out faster?
The best way to make your period come faster is to take your placebo birth control pills earlier than usual. You can also make your period come faster by having sex or relieving stress through exercise or meditation.
Can Bredicon Tablet 0.075 mg cause weight gain?
Bredicon Tablet 0.075 mg containing desogestrel and gestodene types of progesterone hormone are suggested as less likely to cause weight gain.
